Aurobindo Pharma gets USFDA nod for Nafcillin injections

Drug firm Aurobindo Pharma said it has received final approval by the US health regulator to manufacture and market Nafcillin for injection used for treating bacterial infections in the American market.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset
moneycontrol.com

Home » News » Business

Dec 28, 2012, 08.26 AM | Source: PTI

Aurobindo Pharma gets USFDA nod for Nafcillin injections

Drug firm Aurobindo Pharma said it has received final approval by the US health regulator to manufacture and market Nafcillin for injection used for treating bacterial infections in the American market.

Like this story, share it with millions of investors on M3

Aurobindo Pharma gets USFDA nod for Nafcillin injections

Drug firm Aurobindo Pharma said it has received final approval by the US health regulator to manufacture and market Nafcillin for injection used for treating bacterial infections in the American market.

Post Your Comments

Share Cancel

Drug firm Aurobindo Pharma said it has received final approval by the US health regulator to manufacture and market Nafcillin for injection used for treating bacterial infections in the American market. The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Nafcillin for injection USP, packaged in 1g and 2g vials and Nafcillin for injection USP 10g/vial pharmacy bulk package, Aurobindo Pharma said in a statement.

Also Read: Plan panel sets $100 bn target for pharma sector by 2020

"The products are ready for launch," it added. These abbreviated new drug applications (ANDAs) have been approved out of the company's unit XII formulation facility in Hyderabad and will be marketed and sold by its US subsidiary AuroMedics Pharma LLC, Aurobindo Pharma said. The company currently has a total of 171 ANDA approvals (145 final approvals including 2 from Aurolife Pharma LLC and 26 tentative approvals), it added.

"Nafcillin for injection is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug," the company said. Shares of Aurobindo Pharma were trading at Rs 192.40 per scrip on BSE, down 0.31 per cent from its previous close.

Aurobindo Pharm stock price

On May 27, 2016, Aurobindo Pharma closed at Rs 763.95, up Rs 19.75, or 2.65 percent. The 52-week high of the share was Rs 891.50 and the 52-week low was Rs 582.00.


The company's trailing 12-month (TTM) EPS was at Rs 26.47 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 28.86. The latest book value of the company is Rs 94.48 per share. At current value, the price-to-book value of the company is 8.09.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Aurobindo Pharma gets USFDA nod for Nafcillin injections

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login